Glycosylation as a strategy to improve antibody-based therapeutics (Q37402407)

20 August 2017

1 reference

title

Glycosylation as a strategy to improve antibody-based therapeutics (English)

1 reference

20 August 2017

1 reference

1 reference

Roy Jefferis

1

1 reference

20 August 2017

1 March 2009

1 reference

Nature Reviews Drug Discovery

20 August 2017

1 reference

20 August 2017

8

1 reference

20 August 2017

226-234

1 reference

20 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd2804

20 August 2017

0 references

cites work

Potent antibody therapeutics by design

1 reference

"Antibodies--Europe. Engineering the next generation of antibodies".

31 March 2020

1 reference

Development trends for monoclonal antibody cancer therapeutics.

31 March 2020

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

31 March 2020

1 reference

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products

31 March 2020

1 reference

Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement

31 March 2020

1 reference

Reduced susceptibility of recombinant polyclonal antibodies to inhibitory anti-variable domain antibody responses.

31 March 2020

1 reference

Human antibody-Fc receptor interactions illuminated by crystal structures

31 March 2020

1 reference

Interactions of immunoglobulins outside the antigen-combining site

31 March 2020

1 reference

Antibody therapeutics: isotype and glycoform selection

31 March 2020

1 reference

FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy.

31 March 2020

1 reference

Fcgamma receptors as regulators of immune responses

31 March 2020

1 reference

Glycosylation of recombinant antibody therapeutics

31 March 2020

1 reference

Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins

31 March 2020

1 reference

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

31 March 2020

1 reference

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

31 March 2020

1 reference

IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides

31 March 2020

1 reference

Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.

31 March 2020

1 reference

Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity

31 March 2020

1 reference

Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution

31 March 2020

1 reference

The impact of glycosylation on the biological function and structure of human immunoglobulins.

31 March 2020

1 reference

Quantitation of the oligosaccharides of human serum IgG from patients with rheumatoid arthritis: a critical evaluation of different methods.

31 March 2020

1 reference

Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

31 March 2020

1 reference

Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.

31 March 2020

1 reference

The antiinflammatory activity of IgG: the intravenous IgG paradox

31 March 2020

1 reference

Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.

31 March 2020

1 reference

A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins

31 March 2020

1 reference

Glycosylation of polyclonal and paraprotein IgG in multiple myeloma

31 March 2020

1 reference

Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients

31 March 2020

1 reference

Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis.

31 March 2020

1 reference

Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry.

31 March 2020

1 reference

The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms.

31 March 2020

1 reference

31 March 2020

1 reference

Double knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC

31 March 2020

1 reference

The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance

31 March 2020

1 reference

Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease

31 March 2020

1 reference

Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequentia

31 March 2020

1 reference

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

31 March 2020

1 reference

Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization

31 March 2020

1 reference

Humanization of an anti-p185HER2 antibody for human cancer therapy

31 March 2020

1 reference

Glycosylation profiling of a therapeutic recombinant monoclonal antibody with two N-linked glycosylation sites using liquid chromatography coupled to a hybrid quadrupole time-of-flight mass spectrometer

31 March 2020

1 reference

Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective

31 March 2020

1 reference

The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex

31 March 2020

1 reference

The structure of a human type III Fcgamma receptor in complex with Fc

31 March 2020

1 reference

Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding

31 March 2020

1 reference

Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1

31 March 2020

1 reference

Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins

31 March 2020

1 reference

The therapeutic use of rituximab in non-Hodgkin's lymphoma

31 March 2020

1 reference

Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions

31 March 2020

1 reference

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

31 March 2020

1 reference

Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity

31 March 2020

1 reference

Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.

31 March 2020

1 reference

High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.

31 March 2020

1 reference

Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies.

31 March 2020

1 reference

A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients

31 March 2020

1 reference

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

31 March 2020

1 reference

The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms

31 March 2020

1 reference

The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H

31 March 2020

1 reference

Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein

31 March 2020

1 reference

Remodelling the oligosaccharide of human IgG antibodies: effects on biological activities

31 March 2020

1 reference

Mannan binding lectin and its interaction with immunoglobulins in health and in disease.

31 March 2020

1 reference

The potential role of mannan-binding lectin in the clearance of self-components including immune complexes

31 March 2020

1 reference

Paradigms for glycan-binding receptors in cell adhesion.

31 March 2020

1 reference

The known unknowns of antigen processing and presentation.

31 March 2020

1 reference

FcRn: the neonatal Fc receptor comes of age.

31 March 2020

1 reference

Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys

31 March 2020

1 reference

Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content

31 March 2020

1 reference

Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function

31 March 2020

1 reference

Two edged role of mannose binding lectin in rheumatoid arthritis: a cross sectional study

31 March 2020

1 reference

12 December 2020

Heterogeneity of recombinant antibodies: linking structure to function

1 reference

12 December 2020

Cell type-specific glycoforms of Fc gamma RIIIa (CD16): differential ligand binding.

1 reference

12 December 2020

Substances reactive with mannose-binding protein (MBP) in sera of patients with rheumatoid arthritis.

1 reference

12 December 2020

A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words

1 reference

12 December 2020

Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII.

1 reference

12 December 2020

Structural and numerical variations of the carbohydrate moiety of immunoglobulin G

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD2804

1 reference

PubMed ID

19247305

Dimensions Publication ID

20 August 2017

0 references

1 reference

PubMed ID

19247305